Updating control strategy after major process changes and tech transfer Updating Control Strategy After Major Process Changes and Tech Transfer The landscape of pharmaceutical manufacturing is continuously evolving due to technological advancements, regulatory changes, and process optimization. As such, managing the Control Strategy is critical for ensuring consistency, compliance, and product quality. This guide focuses on the regulatory expectations surrounding the updating of control strategies, particularly in the context of major process changes and technology transfers, aligning with the mandates of the FDA, EMA, MHRA, and ICH guidelines. Regulatory Affairs Context Control Strategy is a fundamental element in Quality by…

Leveraging platform control strategies across related product families Leveraging platform control strategies across related product families In today’s rapidly evolving pharmaceutical landscape, the effective management of Critical Quality Attributes (CQAs) and Critical Process Parameters (CPPs) is essential for maintaining product quality and regulatory compliance. By establishing robust CMC control strategies, pharmaceutical companies can streamline their development processes and enhance product lifecycle management. This regulatory explainer manual provides a structured approach to understanding the guidelines and expectations surrounding CMC control strategies across related product families in the US, UK, and EU. Regulatory Affairs Context Regulatory Affairs (RA) professionals play a critical…

Regulatory expectations for justification of CPP ranges and set points Regulatory expectations for justification of CPP ranges and set points Context The control strategy (CS) defined within a product’s CMC (Chemistry, Manufacturing, and Controls) documentation plays a pivotal role in ensuring the quality of pharmaceutical products. Central to this control strategy are critical quality attributes (CQAs) and critical process parameters (CPPs). CQAs are the physical, chemical, biological, or microbiological properties or characteristics that must be controlled throughout the manufacturing process to ensure the desired product quality. CPPs, on the other hand, are the parameters that influence the CQAs and must…

Integrating Device and Container Closure Controls into Product Strategy Integrating Device and Container Closure Controls into Product Strategy In the realm of pharmaceutical and biotech product development, a comprehensive understanding of the CMC (Chemistry, Manufacturing, and Controls) lifecycle management is pivotal. This article delves into the integration of device and container closure controls into product strategy, specifically focusing on critical quality attributes (CQAs) and critical process parameters (CPPs). Regulatory expectations from agencies such as the FDA, EMA, and MHRA will be examined, providing a detailed resource to facilitate the successful registration and maintenance of pharmaceutical products. Context The integration of…

Auditor and Inspector Perspectives on Effective Control Strategies Auditor and Inspector Perspectives on Effective Control Strategies Regulatory Affairs Context The landscape of pharmaceutical and biotechnology development is increasingly complex, necessitating rigorous adherence to regulatory frameworks such as the FDA, the EMA, and the MHRA. Central to this regulatory milieu is the concept of CMC (Chemistry, Manufacturing, and Control) control strategies, which are vital in ensuring the quality, safety, and efficacy of pharmaceuticals. This article outlines critical aspects of effective control strategies, including Critical Quality Attributes (CQAs) and Critical Process Parameters (CPPs), and offers insights into regulatory expectations and best practices….